PND72 EVOLUTION OF THE CONSUMPTION OF ANTIEPILETEC DRUGS IN MOROCCO FROM 2004 TO 2016

Abstract

In 2015, the prevalence of epilepsy is estimated on about of 0.1% in the Moroccan general population. Whenever the disease remains unknown and patients are stigmatized or linked on spiritual beliefs. The Purpose of this study is to establish the profile and trend of evolution of antiepileptic drugs consumption. The system of classification ATC/DDD has been used as recommended by the WHO. The private data sales were extracted from IMS Health for Morocco and the hospital data were obtained from the ministry of health. The data initially expressed in unit of sales were then converted into DDD/1000inhab/Day. With a dozen of substances distributed in six classes ATC4, the private consumption of antiepileptic drugs is increasing (+61.35% in volume and 246.45% in value). The ‘’other antiepileptic class’’ show the important increasing (+4870% in volume), in addition to the fatty acid derivatives (+189%) and the carboxamides derivatives (+70%). Barbiturates recorded a low increasing (+2%). Benzodiazepines recorded a decreasing evolution (-84%). Only three substances (PHENOBARBITAL, VALPROIC ACID and CARBAMAZEPINE) have been tendered by the ministry of health at the hospital level. The general purchase increased for all substances, rising from 0.09DDD/1000inhab/Day in 2004 to 0.62DDD/1000inhab/Day in 2016. The public and private sector consumption shows predominance of private sector consumption but also the growing trend in public sector consumption (from 7% in 2004 to 25% in 2016). The three AED represent about 94% of the private consumption and the totality of public purchases The generics consumption progress since 2007 although it remains relatively low (14% in 2016). Considering the results of this work, the evolution of antiepileptic drugs consumption is largely linked to the consumption of the new antiepileptic drugs and to the consumption of generic antiepileptic drugs, especially coming from 2009.